13F filer · CIK 1839209
Darwin Global Management, Ltd.
ST. HELIER, Y9 · filing since Q4 2020 · last filing Aug 14, 2026
Reported value
$3.8B
$-10.4M vs prior
Positions
5
New / sold out
0 / 1
Added / reduced
3 / 2
Turnover
28.9%
buys $1.6B · sells $1.1B
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | REVOLUTION MEDICINES INC | +8,418,804 | +380.8% | +$1.6B |
| Added | ABIVAX SA | +152,926 | +4.4% | +$14.7M |
| Added | BELITE BIO INC | +19,807 | +0.6% | +$2.9M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | INSMED INC | -10,374,021 | -61.7% | $-1.1B |
| Reduced | ROIVANT SCIENCES LTD | -50,000 | -0.7% | $-1.7M |
| Sold out | DIANTHUS THERAPEUTICS INC | -17,357 | -100.0% | $-1.5M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INCCOM | 10,629,822 | $2.0B | 54.45% |
| 2 | INSMED INCCOM PAR $.01 | 6,431,163 | $673.6M | 17.91% |
| 3 | BELITE BIO INCSPONSORED ADS | 3,077,219 | $456.6M | 12.14% |
| 4 | ABIVAX SASPONSORED ADS | 3,621,583 | $348.2M | 9.26% |
| 5 | ROIVANT SCIENCES LTDSHS | 6,747,300 | $234.3M | 6.23% |